Home Cart Sign in  
Chemical Structure| 1402837-78-8 Chemical Structure| 1402837-78-8

Structure of Navoximod
CAS No.: 1402837-78-8

Chemical Structure| 1402837-78-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IDO-IN-7 is a potent human IDO inhibitor with IC50 of < 1 μM.

Synonyms: GDC-0919; NLG-919

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Navoximod

CAS No. :1402837-78-8
Formula : C18H21FN2O2
M.W : 316.37
SMILES Code : O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3
Synonyms :
GDC-0919; NLG-919
MDL No. :MFCD29472253

Safety of Navoximod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
UM-SCC1 cells 10 µM Assessed the effect of Navoximod nanoformulation on the metabolic activity of UM-SCC1 cells, showing no changes up to 10 μM. Bioeng Transl Med. 2023 Oct 28;9(1):e10599.
UM-SCC1 cells 10 µM Evaluated the efficiency of Navoximod nanoformulation in inhibiting the IDO enzyme, showing an IC50 of 3.33 μM for the nanoformulation compared to 6.66 μM for free Navoximod. Bioeng Transl Med. 2023 Oct 28;9(1):e10599.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Orthotopic head and neck cancer model 10 mg/kg Six doses of Navoximod nanoformulation and four doses of aPD-1 Evaluated the anti-tumor effects of Navoximod nanoformulation in combination with aPD-1, showing significant inhibition of tumor growth with an average tumor volume of 52.7 ± 25.8 mm3 in the combination group compared to single therapy and control groups. Bioeng Transl Med. 2023 Oct 28;9(1):e10599.
C57BL/6J male mice Intra-abdominal sepsis model induced by caecal ligation and puncture (CLP) or lipopolysaccharide (LPS) injection Oral 100 mg/kg and 200 mg/kg Started 48 hours before CLP or LPS injection, once every 24 hours, continued until the end of the experiment Navoximod significantly mitigated IAS-induced skeletal muscle loss and increased the phosphorylated AKT and myosin heavy chain protein expression. J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):1046-1059
C57BL/6 mice Subcutaneous HCC model Intratumoral injection 120 μg Single dose To evaluate the anti-tumor effect of Navoximod combined with HSV-1, results showed that the combination therapy significantly inhibited tumor growth and improved survival rate. Commun Biol. 2023 Jun 9;6(1):621
C57BL/6 mice Intracranial and subcutaneous TRP tumor models Oral 200 mg/kg Twice daily for 2-3 weeks To evaluate the anti-tumor efficacy of GDC-0919 alone or in combination with radiation therapy (RT). Results showed that GDC-0919 alone had no anti-tumor activity but significantly enhanced therapeutic response when combined with RT, particularly with a hypofractionated regimen. Clin Cancer Res. 2018 Aug 1;24(15):3632-3643

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.16mL

0.63mL

0.32mL

15.80mL

3.16mL

1.58mL

31.61mL

6.32mL

3.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories